Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias.

Chaudhury S, O'Connor C, Cañete A, Bittencourt-Silvestre J, Sarrou E, Prendergast Á, Choi J, Johnston P, Wells CA, Gibson B, Keeshan K.

Nat Commun. 2018 Dec 11;9(1):5280. doi: 10.1038/s41467-018-07584-1.


Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32028. [Epub ahead of print]


Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.

Foulkes DM, Byrne DP, Yeung W, Shrestha S, Bailey FP, Ferries S, Eyers CE, Keeshan K, Wells C, Drewry DH, Zuercher WJ, Kannan N, Eyers PA.

Sci Signal. 2018 Sep 25;11(549). pii: eaat7951. doi: 10.1126/scisignal.aat7951.


Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis.

Salomé M, Hopcroft L, Keeshan K.

Exp Hematol. 2018 Oct;66:63-78.e13. doi: 10.1016/j.exphem.2018.07.005. Epub 2018 Jul 20.


A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.

Salomé M, Magee A, Yalla K, Chaudhury S, Sarrou E, Carmody RJ, Keeshan K.

Cell Death Dis. 2018 May 1;9(5):443. doi: 10.1038/s41419-018-0467-3.


Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.

Newcombe AA, Gibson BES, Keeshan K.

Exp Hematol. 2018 Jul;63:1-11. doi: 10.1016/j.exphem.2018.03.008. Epub 2018 Mar 30. Review.


Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2.

O'Connor C, Yalla K, Salomé M, Moka HA, Castañeda EG, Eyers PA, Keeshan K.

Oncotarget. 2018 Feb 19;9(19):14977-14992. doi: 10.18632/oncotarget.24525. eCollection 2018 Mar 13.


Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.

Laing AA, Harrison CJ, Gibson BES, Keeshan K.

Exp Hematol. 2017 Oct;54:40-50. doi: 10.1016/j.exphem.2017.06.007. Epub 2017 Jun 28. Review.


The Tribble with APL: A New Road to Therapy.

Carmody R, Keeshan K.

Cancer Cell. 2017 May 8;31(5):612-613. doi: 10.1016/j.ccell.2017.04.011.


Regulation of NF-κB by PML and PML-RARα.

Ahmed A, Wan X, Mitxitorena I, Lindsay AJ, Paolo Pandolfi P, McCaffrey MW, Keeshan K, Chen YH, Carmody RJ.

Sci Rep. 2017 Mar 20;7:44539. doi: 10.1038/srep44539.


Tribbles in the 21st Century: The Evolving Roles of Tribbles Pseudokinases in Biology and Disease.

Eyers PA, Keeshan K, Kannan N.

Trends Cell Biol. 2017 Apr;27(4):284-298. doi: 10.1016/j.tcb.2016.11.002. Epub 2016 Nov 28. Review.


Human TRIB2 Oscillates during the Cell Cycle and Promotes Ubiquitination and Degradation of CDC25C.

Liang KL, Paredes R, Carmody R, Eyers PA, Meyer S, McCarthy TV, Keeshan K.

Int J Mol Sci. 2016 Aug 23;17(9). pii: E1378. doi: 10.3390/ijms17091378.


TRIB2 regulates normal and stress-induced thymocyte proliferation.

Liang KL, O'Connor C, Veiga JP, McCarthy TV, Keeshan K.

Cell Discov. 2016 Mar 15;2:15050. doi: 10.1038/celldisc.2015.50. eCollection 2016.


Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.

Keeshan K, Vieugué P, Chaudhury S, Rishi L, Gaillard C, Liang L, Garcia E, Nakamura T, Omidvar N, Kogan SC.

Haematologica. 2016 Oct;101(10):1228-1236. Epub 2016 Jul 6.


The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia.

O'Connor C, Lohan F, Campos J, Ohlsson E, Salomè M, Forde C, Artschwager R, Liskamp RM, Cahill MR, Kiely PA, Porse B, Keeshan K.

Oncogene. 2016 Oct 6;35(40):5272-5281. doi: 10.1038/onc.2016.66. Epub 2016 Mar 21.


TRIB2 and the ubiquitin proteasome system in cancer.

Salomè M, Campos J, Keeshan K.

Biochem Soc Trans. 2015 Oct;43(5):1089-94. doi: 10.1042/BST20150103. Review.


Insights into cell ontogeny, age, and acute myeloid leukemia.

Chaudhury SS, Morison JK, Gibson BE, Keeshan K.

Exp Hematol. 2015 Sep;43(9):745-55. doi: 10.1016/j.exphem.2015.05.008. Epub 2015 Jun 5. Review.


Nfix expression critically modulates early B lymphopoiesis and myelopoiesis.

O'Connor C, Campos J, Osinski JM, Gronostajski RM, Michie AM, Keeshan K.

PLoS One. 2015 Mar 17;10(3):e0120102. doi: 10.1371/journal.pone.0120102. eCollection 2015.


Knockdown of interleukin-1 receptor 1 is not neuroprotective in the 6-hydroxydopamine striatal lesion rat model of Parkinson's disease.

Walsh S, Gavin A, Wyatt S, O'Connor C, Keeshan K, Nolan YM, O'Keeffe GW, Sullivan AM.

Int J Neurosci. 2015 Jan;125(1):70-7. doi: 10.3109/00207454.2014.904304. Epub 2014 Apr 14.


Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation.

Rishi L, Hannon M, Salomè M, Hasemann M, Frank AK, Campos J, Timoney J, O'Connor C, Cahill MR, Porse B, Keeshan K.

Blood. 2014 Apr 10;123(15):2389-400. doi: 10.1182/blood-2013-07-511683. Epub 2014 Feb 10.


The functionally diverse roles of tribbles.

Lohan F, Keeshan K.

Biochem Soc Trans. 2013 Aug;41(4):1096-100. doi: 10.1042/BST20130105. Review.


Tribbles in acute leukemia.

Liang KL, Rishi L, Keeshan K.

Blood. 2013 May 23;121(21):4265-70. doi: 10.1182/blood-2012-12-471300. Epub 2013 Apr 2. Review.


Negative regulation of TLX by IL-1β correlates with an inhibition of adult hippocampal neural precursor cell proliferation.

Ryan SM, O'Keeffe GW, O'Connor C, Keeshan K, Nolan YM.

Brain Behav Immun. 2013 Oct;33:7-13. doi: 10.1016/j.bbi.2013.03.005. Epub 2013 Mar 16.


Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL.

Hannon MM, Lohan F, Erbilgin Y, Sayitoglu M, O'Hagan K, Mills K, Ozbek U, Keeshan K.

Br J Haematol. 2012 Sep;158(5):626-34. doi: 10.1111/j.1365-2141.2012.09222.x. Epub 2012 Jul 6.


Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding.

Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, Toscano K, Uljon SN, Blacklow SC, Pear WS.

Blood. 2010 Dec 2;116(23):4948-57. doi: 10.1182/blood-2009-10-247361. Epub 2010 Aug 30.


Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia.

Dedhia PH, Keeshan K, Uljon S, Xu L, Vega ME, Shestova O, Zaks-Zilberman M, Romany C, Blacklow SC, Pear WS.

Blood. 2010 Aug 26;116(8):1321-8. doi: 10.1182/blood-2009-07-229450. Epub 2010 Apr 21.


Tribbles homolog 2 (Trib2) and HoxA9 cooperate to accelerate acute myelogenous leukemia.

Keeshan K, Shestova O, Ussin L, Pear WS.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):119-21. Epub 2007 Nov 7.


Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

Wouters BJ, Jordà MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, Langerak AW, He Y, Yashiro-Ohtani Y, Zhang P, Hetherington CJ, Verhaak RG, Valk PJ, Löwenberg B, Tenen DG, Pear WS, Delwel R.

Blood. 2007 Nov 15;110(10):3706-14. Epub 2007 Aug 1.


Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.

Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, Rodriguez CG, Maillard I, Tobias JW, Valk P, Carroll M, Aster JC, Delwel R, Pear WS.

Cancer Cell. 2006 Nov;10(5):401-11.


The requirement for Notch signaling at the beta-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor.

Maillard I, Tu L, Sambandam A, Yashiro-Ohtani Y, Millholland J, Keeshan K, Shestova O, Xu L, Bhandoola A, Pear WS.

J Exp Med. 2006 Oct 2;203(10):2239-45. Epub 2006 Sep 11.


Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Ferrari-Amorotti G, Keeshan K, Zattoni M, Guerzoni C, Iotti G, Cattelani S, Donato NJ, Calabretta B.

Blood. 2006 Aug 15;108(4):1353-62. Epub 2006 May 2.


The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression.

Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, Brown EJ, Hess JL, Pear WS, Hua X.

Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1018-23. Epub 2006 Jan 13.


Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.

Keeshan K, Cotter TG, McKenna SL.

Br J Haematol. 2003 Oct;123(1):34-44.


Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation.

Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B.

Blood. 2003 Aug 15;102(4):1267-75. Epub 2003 Apr 17.


High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.

Keeshan K, Cotter TG, McKenna SL.

Leukemia. 2002 Sep;16(9):1725-34.


Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.

Keeshan K, Mills KI, Cotter TG, McKenna SL.

Leukemia. 2001 Dec;15(12):1823-33.


Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.

Di Bacco A, Keeshan K, McKenna SL, Cotter TG.

Oncologist. 2000;5(5):405-15. Review.

Supplemental Content

Loading ...
Support Center